Pharvaris BV Net Assets
Pharvaris BV net assets. Based on the latest financial reports, Pharvaris BV (PHVS) has net assets worth $300.81 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($328.67 Million) and total liabilities ($27.86 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Pharvaris BV annual equity growth to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $300.81 Million |
| % of Total Assets | 91.52% |
| Annual Growth Rate | 66.21% |
| 5-Year Change | 32.36% |
| 10-Year Change | N/A |
| Growth Volatility | 151.18 |
Net Assets of Pharvaris BV (2017–2025)
Net assets of Pharvaris BV from 2017 to 2025. This chart illustrates how Pharvaris BV's net assets have evolved over time, based on quarterly financial data. See PHVS equity to assets ratio to measure how much of total assets are equity-financed.
Annual Net Assets for Pharvaris BV (2017–2025)
The table below shows the annual net assets of Pharvaris BV from 2017 to 2025. For live market cap and overall valuation, see PHVS market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $271.27 Million | +1.31% |
| 2024-12-31 | $267.76 Million | -30.28% |
| 2023-12-31 | $384.05 Million | +157.30% |
| 2022-12-31 | $149.26 Million | -27.17% |
| 2021-12-31 | $204.95 Million | +113.97% |
| 2020-12-31 | $95.79 Million | +412.95% |
| 2019-12-31 | $18.67 Million | +277.01% |
| 2018-12-31 | $4.95 Million | +6.35% |
| 2017-12-31 | $4.66 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Pharvaris BV's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 57346313300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Pharvaris BV Net Assets Breakdown (December 2025)
Pharvaris BV net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $7.83 Million | 2.88% |
| Other Comprehensive Income | $50.50 Million | 18.61% |
| Other Components | $792.55 Million | 292.16% |
| Total Equity | $271.27 Million | 100.00% |
Pharvaris BV Competitors by Market Cap
The table below lists competitors of Pharvaris BV ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
State Grid Information&Communication Co Ltd
SHG:600131
|
$2.44 Billion |
|
Shanghai Bright Power Semiconductor
SHG:688368
|
$2.44 Billion |
|
OneStream, Inc. Class A Common Stock
NASDAQ:OS
|
$2.44 Billion |
|
Santos Brasil Participações S.A
SA:STBP3
|
$2.45 Billion |
|
Bure Equity AB
ST:BURE
|
$2.44 Billion |
|
Kalpataru Projects International Ltd.
NSE:KPIL
|
$2.44 Billion |
|
Zhejiang Provincial New Energy Investment Group Co Ltd
SHG:600032
|
$2.44 Billion |
|
Fastly, Inc. Class A Common Stock
NYSE:FSLY
|
$2.44 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Pharvaris BV's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 267,760,741 to 271,274,334, a change of 3,513,593 (1.3%).
- Net loss of 175,699,397 reduced equity.
- New share issuances of 171,737,647 increased equity.
- Other comprehensive income increased equity by 10,647,140.
- Other factors decreased equity by 3,171,797.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-175.70 Million | -64.77% |
| Share Issuances | $171.74 Million | +63.31% |
| Other Comprehensive Income | $10.65 Million | +3.92% |
| Other Changes | $-3.17 Million | -1.17% |
| Total Change | $- | 1.31% |
Book Value vs Market Value Analysis
This analysis compares Pharvaris BV's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.58x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 227.91x to 7.58x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $0.15 | $34.78 | x |
| 2018-12-31 | $0.16 | $34.78 | x |
| 2019-12-31 | $0.59 | $34.78 | x |
| 2020-12-31 | $3.14 | $34.78 | x |
| 2021-12-31 | $6.74 | $34.78 | x |
| 2022-12-31 | $4.44 | $34.78 | x |
| 2023-12-31 | $10.00 | $34.78 | x |
| 2024-12-31 | $4.96 | $34.78 | x |
| 2025-12-31 | $4.59 | $34.78 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Pharvaris BV utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -64.77%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.11x
- Recent ROE (-64.77%) is below the historical average (-47.41%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -87.10% | 0.00% | 0.00x | 1.10x | $-4.81 Million |
| 2019 | -48.11% | 0.00% | 0.00x | 1.10x | $-10.85 Million |
| 2020 | -30.93% | 0.00% | 0.00x | 1.06x | $-39.20 Million |
| 2021 | -20.85% | 0.00% | 0.00x | 1.03x | $-63.23 Million |
| 2022 | -51.14% | 0.00% | 0.00x | 1.12x | $-91.26 Million |
| 2023 | -26.27% | 0.00% | 0.00x | 1.04x | $-139.28 Million |
| 2024 | -50.13% | 0.00% | 0.00x | 1.09x | $-161.00 Million |
| 2025 | -64.77% | 0.00% | 0.00x | 1.11x | $-202.83 Million |
Industry Comparison
This section compares Pharvaris BV's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $154,916,114
- Average return on equity (ROE) among peers: -15.75%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Pharvaris BV (PHVS) | $300.81 Million | -87.10% | 0.09x | $2.44 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $26.78 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $243.03 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $225.18 Million | -44.68% | 0.02x | $16.93 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $40.92 Million | 73.18% | 0.29x | $768.65 Million |
| ABVC Biopharma Inc (ABVC) | $29.08K | -111.02% | 1.35x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.74 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $182.13 Million | -20.84% | 0.04x | $3.54 Billion |
About Pharvaris BV
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and a… Read more